As medical weight loss continues to evolve in 2026, the landscape of GLP-1 therapies has reached a pivotal moment with ...

Waymo is rapidly expanding, processing over 450,000 paid rides per week, and is reportedly in talks to raise over $15 billion ...

Pfizer ( PFE +0.24%) pays a dividend that yields around 6.8%. While the yield has been pushed higher as share prices have ...

Older adults with type 2 diabetes who started taking certain newer medications—such as empagliflozin (Jardiance), dapagliflozin (Farxiga), semaglutide (Ozempic), or liraglutide (Victoza)—were less ...

The FDA granted accelerated approval for the subcutaneous formulation of mosunetuzumab (Lunsumio VELO) for certain patients ...

CMS released plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s ...

Amber Carter had battled with her weight for as long as she could remember. For decades, the 39-year-old from Clarkston, Michigan, had been caught in a frustrating cycle: eating a balanced diet, ...

Serena Williams is using weight-loss medication, and people have a lot of thoughts about that. “I was never able to be at a healthy weight, whether it was my joints or blood sugar levels,” she said on ...

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) formally approved Wegovy® pills, marking a major milestone in obesity treatment. The new medication from Novo Nordisk is designed as a ...

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...